相关临床试验
6
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1991
进行中（未招募）
1
16.7%
已完成
4
66.7%
尚未招募
1
16.7%
暂无批准数据
- A comprehensive analysis of 23,211 breast cancer patients from 19 clinical trials found that proton pump inhibitors (PPIs) used for heartburn treatment were associated with 19% higher risk of death and 36% increased risk of serious adverse events. - The study revealed that common cardiovascular medications including beta-blockers and ACE inhibitors increased severe side effects but did not impact overall survival rates. - Researchers emphasize the need for careful medication review in breast cancer patients, as many manage multiple chronic conditions requiring various medications alongside cancer treatment. - The findings highlight potential drug interactions that could compromise cancer treatment effectiveness, though patients should not discontinue medications without medical consultation.
- University of South Australia researchers found that eating two eggs daily as part of a low saturated fat diet actually lowered LDL cholesterol levels compared to control diets. - The study revealed saturated fat, not dietary cholesterol from eggs, is the primary driver of elevated LDL cholesterol levels in the blood. - Results showed each 1-gram increase in saturated fat was associated with a 0.35-point increase in LDL cholesterol, while no significant relationship existed between cholesterol intake and LDL levels. - The egg diet also increased beneficial carotenoids lutein and zeaxanthin in plasma, which support brain and eye health while protecting against inflammation.
- Scientists at the University of South Australia, led by Indian-origin researchers, have developed a once-weekly injectable formulation that delivers levodopa and carbidopa for Parkinson's disease treatment. - The biodegradable gel formulation releases over 90% of levodopa and 81% of carbidopa steadily over seven days, potentially replacing multiple daily pills for over eight million Parkinson's patients worldwide. - The injectable uses FDA-approved PLGA polymer and can be administered through a fine 22-gauge needle, showing over 80% degradation within a week with no significant toxicity in laboratory tests. - The technology could be adapted for other chronic conditions including cancer, diabetes, and neurodegenerative disorders that require long-term drug delivery.
- University of South Australia researchers have developed a phospholipid complex that increases cannabidiol solubility by up to six times, significantly enhancing its absorption in the gastrointestinal tract. - The breakthrough formulation showed 67.1% dissolution in water within three hours and 32.7% higher permeability through intestinal walls compared to unmodified CBD, potentially reducing required dosages and side effects. - Unlike traditional CBD formulations that degrade when exposed to heat, light, or oxygen, the new CBD-PLC maintained stability over 12 months of testing under varied storage conditions, making it more reliable for pharmaceutical applications.
- University of Wollongong researchers received $500,000 from Australian Economic Accelerate Ignite Grants to develop ResectAssist™, a biodegradable implantable device for inoperable pancreatic cancer. - The device delivers high-dose chemotherapy directly into tumors using standard endoscopy techniques, aiming to convert non-resectable pancreatic tumors to resectable ones. - ResectAssist™-FOLFIRINOX delivers the FOLFIRINOX chemotherapy regimen locally to maximize anti-cancer efficacy while minimizing systemic side effects. - The collaboration between UOW and FivepHusion targets pancreatic cancer, which has survival rates under 10% and represents one of the most challenging cancers to treat.
